Insilico Enters Into A Collaboration With APRINOIA To Apply Novel Generative AI-powered System

Insilico Medicine is pleased to announce that it has entered into a research collaboration with APRINOIA Therapeutics to utilize Insilico's novel generative artificial intelligence (AI) technology to accelerate the discovery of next generation compounds targeting abnormal proteins in brain associated with neurodegenerative diseases. With a mission to accelerate drug discovery and development, Insilico Medicine has been breaking new grounds with its next-generation AI technologies and expanding international partnerships in the US, Europe and Asia Pacific Region. "APRINOIA discovers and develops first-in-class diagnostics and therapeutics that can be broadly applied as PET tracers in the field of neurodegenerative diseases. We are glad to collaborate with APRINOIA, where we will apply our Chemistry42 suite to design a new generation of PET tracers with desired properties. Through this collaboration, we will further demonstrate the universality of our AI-powered generative chemistry platform," said Jimmy Yen-Chu Lin, PhD, CEO of Insilico Medicine Taiwan. "We are excited to initiate the collaboration with Insilico to enrich APRINOIA's proprietary collection of compounds for neurodegeneration," said Dr. Ming-Kuei Jang, CEO of APRINOIA. "Early diagnosis is critical for disease management. Our initial focus is to discover novel imaging PET tracers to quantify and visualize pathologies of abnormal proteins in the brain. With Insilico's AI-powered platform, we are hoping to shorten the time from lab to clinics to benefit patients and in the medical communities." By leveraging an integrated AI-driven drug discovery approach, Insilico Medicine provides APRINOIA Therapeutics with an effective, rational, external auxiliary solution for driving programs forward. The partnership between APRINOIA and Insilico will include an upfront fee and performance-based milestones.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!